Scholarlink

<p>Osteoarthritis (OA) is a common degenerative joint disease with no curative treatments and a poorly understood etiology. Here, we report that defective sulfation, a largely underexplored chemical modification of lipid metabolites, drives pathogenic lipid accumulation in chondrocytes to promote OA. Intrigued by observations of lipid droplet accumulation in cartilage from genetically modified male mice with sulfation defects, we identified that the production and sulfation status of 25-hydroxycholesterol (25HC), an oxysterol metabolite, could impact OA risk and development. Transcriptomics and peptide-centric local stability assays revealed that 25HC and its sulfated derivative (25HC3S) exhibited opposing regulatory effects on lipid biosynthesis genes and distinct protein interaction profiles. Mechanistically, 25HC activated Liver X Receptor (LXR) ligand-dependently to potentiate lipid synthesis and uptake, while 25HC3S deactivated LXR by altering its nuclear localization and promoting nucleolar sequestration, thus mitigating chondrocyte lipid accumulation and cartilage damage. Moreover, human studies linked genetic variants in 25HC sulfation pathways to OA risk, with concomitantly reduced sulfation gene expression and increased lipid accumulation in OA cartilage. These findings support an oxysterol undersulfation model wherein defective oxysterol sulfation unleashes nuclear oxysterol receptor activation to drive pathogenic chondrocyte lipid accumulation, and highlight the therapeutic potential of 25HC3S against OA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oxysterol undersulfation promotes osteoarthritis by fueling chondrocyte lipid accumulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Huanbo Wang,
  • Bowei Ni,
  • Yu Qian,
  • Guangyu Ding,
  • Ting He,
  • Xinyu Zhang,
  • Hailun Xu,
  • Xue Hao,
  • Yaqian Hu,
  • Di Wang,
  • Qiang Jie,
  • Ying Li,
  • Tianyang Jie,
  • Zhong Alan Li,
  • Zhuojing Luo,
  • Houfeng Zheng,
  • Liu Yang,
  • Chao Zheng

摘要

Osteoarthritis (OA) is a common degenerative joint disease with no curative treatments and a poorly understood etiology. Here, we report that defective sulfation, a largely underexplored chemical modification of lipid metabolites, drives pathogenic lipid accumulation in chondrocytes to promote OA. Intrigued by observations of lipid droplet accumulation in cartilage from genetically modified male mice with sulfation defects, we identified that the production and sulfation status of 25-hydroxycholesterol (25HC), an oxysterol metabolite, could impact OA risk and development. Transcriptomics and peptide-centric local stability assays revealed that 25HC and its sulfated derivative (25HC3S) exhibited opposing regulatory effects on lipid biosynthesis genes and distinct protein interaction profiles. Mechanistically, 25HC activated Liver X Receptor (LXR) ligand-dependently to potentiate lipid synthesis and uptake, while 25HC3S deactivated LXR by altering its nuclear localization and promoting nucleolar sequestration, thus mitigating chondrocyte lipid accumulation and cartilage damage. Moreover, human studies linked genetic variants in 25HC sulfation pathways to OA risk, with concomitantly reduced sulfation gene expression and increased lipid accumulation in OA cartilage. These findings support an oxysterol undersulfation model wherein defective oxysterol sulfation unleashes nuclear oxysterol receptor activation to drive pathogenic chondrocyte lipid accumulation, and highlight the therapeutic potential of 25HC3S against OA.